About Dr. Cao Guangwen
Dr. Cao Guangwen (曹广文) is a Professor, Doctoral Supervisor, and one of China's foremost epidemiologists and cancer prevention scientists, based at the Department of Epidemiology, Changhai Hospital, Naval Medical University (Second Military Medical University). Internationally recognized as a leading authority on the epidemiology of viral hepatitis and hepatitis-related cancers — particularly hepatocellular carcinoma (HCC) driven by chronic hepatitis B virus (HBV) infection — Dr. Cao has produced a body of research that has fundamentally shaped the understanding of HBV molecular evolution, HBV-related carcinogenesis, and population-level strategies for hepatitis B control and liver cancer prevention in China and globally.
Dr. Cao's research program sits at the intersection of molecular epidemiology, virology, and cancer biology. His landmark studies on HBV genotype distribution and clinical outcomes in Chinese populations, the molecular mechanisms by which specific HBV mutations — including precore, basal core promoter, and surface antigen mutations — drive hepatocellular carcinogenesis, and the population-level impact of HBV vaccination and antiviral therapy on liver cancer incidence have been published in leading international journals and have directly informed national and international hepatitis B management guidelines and liver cancer prevention strategies.
For international patients — particularly those with chronic hepatitis B who are concerned about their liver cancer risk, those with a family history of HBV-related liver cancer, and those seeking evidence-based guidance on HBV monitoring, antiviral therapy, and HCC surveillance — Dr. Cao's unique combination of epidemiological expertise and clinical knowledge of HBV-related disease provides a perspective on risk assessment and prevention that is rarely available outside major academic hepatology and epidemiology centers.
Hospital Affiliation: Department of Epidemiology, Changhai Hospital
Changhai Hospital (长海医霂), affiliated with Naval Medical University, is one of Shanghai's largest and most prestigious academic medical centers. Its Department of Epidemiology — led by Dr. Cao Guangwen — is one of China's most productive and internationally recognized epidemiology research programs, with particular strength in infectious disease epidemiology, cancer epidemiology, and molecular epidemiology. The department maintains active research collaborations with epidemiology and public health centers across China and internationally, and participates in national and international cohort studies, case-control studies, and intervention trials evaluating hepatitis B control, liver cancer prevention, and other public health priorities.
The department's molecular epidemiology laboratory is equipped for HBV genotyping, HBV mutation analysis, HBV viral load quantification, and the molecular characterization of HBV strains associated with different clinical outcomes — capabilities that enable the precise assessment of individual HBV-related cancer risk that is the foundation of Dr. Cao's clinical consultation service for international patients with chronic hepatitis B.
Clinical Specialties: What Dr. Cao Guangwen Provides
- HBV-related liver cancer risk assessment — comprehensive individual risk assessment for HCC in patients with chronic hepatitis B, integrating HBV genotype, viral load, HBeAg/anti-HBe status, HBV mutation profile (precore, basal core promoter, surface antigen mutations), liver fibrosis stage, family history of HCC, alcohol use, metabolic risk factors, and demographic characteristics; risk stratification using validated HCC prediction models (CU-HCC, GAG-HCC, REACH-B, PAGE-B) adapted for Chinese and Asian populations; individualized HCC surveillance recommendations based on risk stratification
- HBV molecular characterization and mutation analysis — HBV genotyping (genotypes A–J) with clinical outcome implications; detection and quantification of precore (G1896A) and basal core promoter (A1762T/G1764A) mutations associated with elevated HCC risk; surface antigen mutation analysis including immune escape mutations; assessment of antiviral resistance mutations; integration of molecular HBV characterization into individualized risk assessment and treatment planning
- HBV antiviral therapy guidance — evidence-based guidance on antiviral therapy initiation, agent selection, and monitoring for chronic hepatitis B, informed by the latest international guidelines (AASLD, EASL, APASL) and Dr. Cao's own research on HBV molecular epidemiology and treatment outcomes; coordination with the infectious disease and hepatology team for antiviral therapy prescription and monitoring
- HCC surveillance program design — individualized HCC surveillance protocol design for patients with chronic hepatitis B and cirrhosis, based on risk stratification and the latest evidence on surveillance modality (ultrasound, CT, MRI) and interval; evaluation of novel HCC surveillance biomarkers including AFP-L3, des-gamma-carboxyprothrombin (DCP/PIVKA-II), and circulating tumor DNA as adjuncts to imaging surveillance
- Family risk assessment and cascade screening — assessment of HCC risk in first-degree relatives of patients with HBV-related liver cancer; coordination of HBV serology testing and HBV vaccination for susceptible family members; HCC surveillance recommendations for at-risk family members; genetic counseling coordination for families with suspected hereditary liver cancer predisposition
- Cancer epidemiology consultation and second opinion — expert epidemiological perspective on cancer risk assessment, cancer causation, and cancer prevention for patients and their physicians; second opinion on HBV management and HCC surveillance strategy for patients managed elsewhere; written English-language risk assessment and surveillance recommendation reports available through CMCS
- Lifestyle and environmental cancer risk modification — evidence-based guidance on modifiable cancer risk factors including alcohol consumption, obesity, metabolic syndrome, aflatoxin exposure, and tobacco use in the context of HBV-related liver cancer risk; integration of lifestyle modification recommendations into the comprehensive HCC prevention strategy
Why International Patients Choose Dr. Cao Guangwen and Changhai Hospital
International patients — particularly those with chronic hepatitis B who are concerned about their liver cancer risk — seek consultation with Dr. Cao Guangwen for a perspective on HBV-related cancer risk that goes beyond standard clinical hepatology to incorporate the molecular epidemiological insights that his research has generated.
For patients with chronic hepatitis B who have been told that their viral load is low or that their liver function tests are normal and therefore their HCC risk is low, Dr. Cao's molecular epidemiological assessment — incorporating HBV genotype, mutation profile, and validated HCC prediction models — frequently reveals a more nuanced risk picture that justifies more intensive surveillance or earlier antiviral therapy than standard clinical assessment would suggest. The identification of high-risk HBV mutations — particularly basal core promoter mutations that are associated with a two- to threefold increase in HCC risk independent of viral load — can fundamentally change the surveillance and treatment strategy for individual patients.
For patients with a family history of HBV-related liver cancer — a strong independent risk factor for HCC that is frequently not adequately incorporated into clinical risk assessment — Dr. Cao's expertise in family risk assessment and cascade screening provides a comprehensive evaluation of familial HCC risk and a tailored surveillance and prevention strategy for the patient and their at-risk family members.
The cost of HBV molecular characterization, risk assessment consultation, and HCC surveillance planning at Changhai Hospital is substantially below that of equivalent services in Western healthcare systems, and access to Dr. Cao's clinic can typically be arranged within days through CMCS.
What to Expect at Your Consultation
Consultations with Dr. Cao Guangwen at Changhai Hospital arranged through CMCS begin with a comprehensive review of all prior hepatitis B records — including HBV serology (HBsAg, HBeAg, anti-HBe, anti-HBs, anti-HBc), HBV DNA quantification, HBV genotype if previously tested, liver function tests and bilirubin trend, complete blood count and platelet count, AFP and other tumor markers, liver imaging (ultrasound, CT, MRI), prior liver biopsy or FibroScan results, prior antiviral treatment history, and family history of hepatitis B and liver cancer — as well as the patient's lifestyle risk factors and relevant comorbidities. CMCS will arrange certified translation of all medical records and investigation results in advance of the consultation.
Dr. Cao will perform a comprehensive HBV molecular characterization where indicated, assess individual HCC risk using validated prediction models, outline a tailored HCC surveillance protocol, provide evidence-based guidance on antiviral therapy, and coordinate family cascade screening where appropriate. A written English-language risk assessment and surveillance recommendation report is provided after every consultation, and CMCS will facilitate direct communication between Dr. Cao's team and the patient's home hepatologist or gastroenterologist for integration of the recommendations into the ongoing care plan.
Book a Consultation Through CMCS
China Medical Concierge Shanghai (CMCS) provides comprehensive end-to-end support for international patients seeking cancer epidemiology and HBV risk assessment consultation with Dr. Cao Guangwen at Changhai Hospital. Our services include priority consultation scheduling, certified medical record and laboratory result translation, coordination of HBV molecular characterization and liver imaging, on-site interpretation throughout the consultation, and written English-language risk assessment and surveillance recommendation reports. CMCS will also facilitate direct communication between Dr. Cao's team and the patient's home physicians to ensure seamless integration of the recommendations into the patient's ongoing hepatitis B and liver cancer prevention care.
📧 contract@medicalsh.com | 💬 WeChat: gezhanglao | 🌐 medicalsh.com
0 comments